docetaxel anhydrous has been researched along with B-Cell Lymphoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Celander, M; Forsberg, G; Hedlund, G; Ohman, MW; Sundstedt, A | 1 |
| Cooke, LS; Liu, X; Mahadevan, D; Miller, TP; Persky, DO; Qi, W; Squires, M | 1 |
| Cooke, LS; Fisher, RI; Mahadevan, D; Manziello, A; Miller, TP; Morales, C; Persky, DO; Qi, W; Stejskal, A | 1 |
| Basu, A; Croce, CM; Haldar, S | 1 |
4 other study(ies) available for docetaxel anhydrous and B-Cell Lymphoma
| Article | Year |
|---|---|
Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
Topics: Animals; Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Agents; Cytotoxicity, Immunologic; Docetaxel; Drug Delivery Systems; Drug Synergism; Enterotoxins; Female; Humans; Immunoglobulin Fab Fragments; Immunotherapy; Lung Neoplasms; Lymphocyte Activation; Lymphoma, B-Cell; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Protein Engineering; Recombinant Fusion Proteins; T-Lymphocytes; Taxoids; Tumor Burden | 2009 |
AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Taxoids; Urea; Xenograft Model Antitumor Assays | 2012 |
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antigens, Nuclear; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Azepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Cyclin D1; Docetaxel; Gene Expression Profiling; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rituximab; Spindle Apparatus; Taxoids; Vincristine; Xenograft Model Antitumor Assays | 2012 |
Bcl2 is the guardian of microtubule integrity.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Chronic Disease; Docetaxel; G2 Phase; Humans; Leukemia; Lymphoma, B-Cell; Male; Microtubules; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Cells, Cultured | 1997 |